Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,077

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

Open access
Vallet-Pichard, Anaïs, Mallet, Vincent, Nalpas, Bertrand, Verkarre, Virginie, Nalpas, Antoine, Dhalluin-Venier, Valérie, Fontaine, Hélène, Pol, Stanislas·2007·Hepatology
DOI 10.1002/hep.21669
Open this paper in CoChat — free account

Abstract

To optimize the management of patients with chronic hepatitis C virus (HCV) infection, noninvasive tests to determine the degree of hepatic fibrosis have been developed. The aims of this study were (1) to validate a simple, inexpensive, noninvasive test called FIB-4, which combines standard biochemical values (platelets, ALT, AST) and age, in a series of 847 liver biopsies performed in HCV-monoinfected patients; and (2) to compare the results of 780 FIB-4 and FibroTests performed the same day in a series of 592 HCV-infected patients. The FIB-4 index enabled the correct identification of patients with severe fibrosis (F3-F4) and cirrhosis with an area under the receiver operating characteristic curve of 0.85 (95% CI 0.82-0.89) and 0.91 (95% CI 0.86-0.93), respectively. An FIB-4 index <1.45 had a negative predictive value of 94.7% to exclude severe fibrosis with a sensitivity of 74.3%. An FIB-4 index higher than 3.25 had a positive predictive value to confirm the existence of a significant fibrosis (F3-F4) of 82.1% with a specificity of 98.2%. Using these ranges, 72.8% of the 847 liver biopsies were correctly classified. The FIB-4 index was strongly correlated to the FibroTest results for a score <1.45 or >3.25 (κ = 0.561, P < 0.01). A FIB-4 value <1.45 or >3.25 (64.6% of the cases) was concordant with FibroTest results in 92.1% and 76%, respectively. Conclusion: For values outside 1.45-3.25, the FIB-4 index is a simple, accurate, and inexpensive method for assessing liver fibrosis and proved to be concordant with FibroTest results. (HEPATOLOGY 2007.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.21669

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 24

  1. Cadranel, 2000, Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF)., HEPATOLOGY, 32, 477, 10.1053/jhep.2000.16602 · DOI · Paper page
  2. Castera, 1999, Pain experienced during percutaneous liver biopsy., HEPATOLOGY, 30, 1529, 10.1002/hep.510300624 · DOI · Paper page
  3. Bravo, 2001, Liver biopsy., N Engl J Med, 344, 495, 10.1056/NEJM200102153440706 · DOI · Paper page
  4. Regev, 2002, Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection., Am J Gastroenterol, 97, 2614, 10.1111/j.1572-0241.2002.06038.x · DOI · Paper page
  5. 1994, The French METAVIR Cooperative Study Group., HEPATOLOGY, 20, 15
  6. Colloredo, 2003, Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease., J Hepatol, 39, 239, 10.1016/S0168-8278(03)00191-0 · DOI · Paper page
  7. Bedossa, 2003, Sampling variability of liver fibrosis in chronic hepatitis C., HEPATOLOGY, 38, 1449, 10.1016/j.hep.2003.09.022 · DOI · Paper page
  8. Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C., HEPATOLOGY, 38, 518, 10.1053/jhep.2003.50346 · DOI · Paper page
  9. Forns, 2002, Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model., HEPATOLOGY, 36, 986, 10.1053/jhep.2002.36128 · DOI · Paper page
  10. ImbertBismut, 2001, Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study., Lancet, 357, 1069, 10.1016/S0140-6736(00)04258-6 · DOI · Paper page
  11. Poynard, 2002, Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial., J Viral Hepat, 9, 128, 10.1046/j.1365-2893.2002.00341.x · DOI
  12. Myers, 2002, Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C., Am J Gastroenterol, 97, 2419, 10.1111/j.1572-0241.2002.05997.x · DOI
  13. Myers, 2003, Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and ageplatelet index., Dig Dis Sci, 48, 146, 10.1023/A:1021702902681 · DOI
  14. Poynard, 2003, Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa2b and ribavirin., HEPATOLOGY, 38, 481, 10.1053/jhep.2003.50319 · DOI · Paper page
  15. Rossi, 2003, Validation of FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients., Clin Chem, 49, 450, 10.1373/49.3.450 · DOI
  16. Castera, 2005, Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C., Gastroenterology, 128, 343, 10.1053/j.gastro.2004.11.018 · DOI · Paper page
  17. Cales, 2005, A novel panel of blood markers to assess the degree of liver fibrosis., HEPATOLOGY, 42, 1373, 10.1002/hep.20935 · DOI · Paper page
  18. Adams, 2005, Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection., Clin Chem, 51, 1867, 10.1373/clinchem.2005.048389 · DOI · Paper page
  19. Poynard, 2005, FibroTestFibroSURE: towards a universal biomarker of liver fibrosis?, Expert Rev Mol Diagn, 5, 15, 10.1586/14737159.5.1.15 · DOI
  20. Torriani, 2004, Peginterferon Alfa2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients., N Engl J Med, 351, 438, 10.1056/NEJMoa040842 · DOI · Paper page
  21. Poynard, 2004, Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C., Clin Chem, 50, 1344, 10.1373/clinchem.2004.032227 · DOI · Paper page
  22. McHutchison, 2000, Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group., J Gastroenterol Hepatol, 15, 945, 10.1046/j.1440-1746.2000.02233.x · DOI
  23. Sebastiani, 2006, Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic hepatitis C., J Hepatol, 44, 686, 10.1016/j.jhep.2006.01.007 · DOI · Paper page
  24. Bourliere, 2006, Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies., J Viral Hepat, 13, 659, 10.1111/j.1365-2893.2006.00736.x · DOI

Cited by

Metadata

Authors
Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-07
Volume
46
Issue
1
Pages
32-36
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.21669
OpenAlex
W2088337379
Cited by
2,077
References
1
FWCI
14.24
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2984 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.